Benjamin Dryden on Government View of Merger Remedies – ‘No secret they are skeptical’
22 April 2024
Foley & Lardner LLP partner Benjamin Dryden assessed the U.S. Department of Justice’s and Federal Trade Commission’s increasingly aggressive scrutiny on mergers in the Law360 article, “What We’ve Learned From Biden-Era Merger Remedies.”
“They’ve made no secret of the fact that they are skeptical of merger remedies,” commented Dryden, who is vice-chair of Foley’s Antitrust & Competition Practice.
He explained that companies have realized that while government agencies are unlikely to accept offered remedies to address competition concerns, “a court might.” As a result, companies are potentially more willing to fight enforcers in court.
(Subscription required)
People
Related News
27 August 2024
In the News
Samuel Goldstick Assesses Data Privacy Challenges for Automakers
Foley & Lardner LLP partner Samuel Goldstick underscored how disclosure can help automakers reduce legal risk in the Automotive Dive article, "Automakers face growing data privacy challenges, experts say."
26 August 2024
In the News
Judith Waltz Quoted on Inflation Reduction Act, Pharma Impact
Foley & Lardner LLP partner Judith Waltz is quoted in the PharmaVoice article, "Pharmas’ IRA court losses mount. They keep pursuing them."
20 August 2024
In the News
Kevin Hyde Featured in Q&A on Jacksonville Legal Market – 'The outlook is good'
Foley & Lardner LLP partner Kevin Hyde is featured in a Capital Analytics Associates Q&A on the major achievements of Foley's Jacksonville office, key trends in the legal market, and the firm's commitment to its talent and client service.